Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
forkhead box L1
(
FOXL1
) transcription factor regulates epithelial proliferation and development of gastrointestinal tract and has been implicated in gastrointestinal tumorigenesis in mouse models. However, the role of
FOXL1
in pancreatic cancer development and progression remains to be elucidated. Here, we report that higher expression of
FOXL1
is significantly associated with better clinical outcome in human pancreatic ductal adenocarcinoma (PDAC). A lower
FOXL1
expression is correlated with metastasis and advanced pathologic stage of pancreatic cancer. Mechanistic analyses showed that overexpression of
FOXL1
induces apoptosis and inhibits proliferation and invasion in pancreatic cancer cells, whereas silencing of
FOXL1
by siRNA inhibits apoptosis and enhances tumor cell growth and invasion. Furthermore,
FOXL1
overexpression significantly suppressed the growth of tumor xenografts in nude mice.
FOXL1
promoted apoptosis partly through the induction of TNF-related apoptosis-inducing ligand (TRAIL) in pancreatic cancer cells. In addition,
FOXL1
suppressed the transcription of zinc finger E-box-binding homeobox 1 (ZEB1), an activator of epithelial-mesenchymal transition, and the negative regulation of ZEB1 contributed to the inhibitory effect of
FOXL1
on tumor cell invasion. Taken together, our findings suggest that
FOXL1
expression is a candidate predictor of clinical outcome in patients with resected PDAC and it plays an inhibitory role in pancreatic
tumor progression
.
...
PMID:FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. 2380 48
